Anticoagulation as a Limitation to New Alzheimer's Disease Anti‐Amyloid Monoclonal Antibodies therapy
Our study reveals that a large number of individuals with AD are on anticoagulation therapy for AFib. Considering the high prevalence of AFib as a cause of anticoagulation therapy, treatment protocols for AFib should prioritize an individualized approach and include early detection of AD. Future AD clinical trials should focus on expanding treatment access for those on anticoagulant while ensuring safety.
Authors
- Sakina Ouedraogo Tall
- RS Osorio
- Tovia Jacobs
- Matin Soeizi
- Zafarullah M Chaudhary
Institutions
- New York City Health and Hospitals Corporation (US)
- New York University (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70860_102086
- Primary Topic
- Intracerebral and Subarachnoid Hemorrhage Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00